Details for New Drug Application (NDA): 207382
✉ Email this page to a colleague
NDA 207382 describes TOPIRAMATE, which is a drug marketed by Actavis Labs Fl, Ajanta Pharma Ltd, Alkem Labs Ltd, Dr Reddys, Endo Operations, Glenmark Pharms Ltd, Lupin Ltd, Zydus, Zydus Pharms, Aurobindo Pharma Ltd, Barr, Chartwell Rx, Strides Pharma, Teva, Twi Pharms, Watson Labs, Zydus Pharms Usa Inc, Accord Hlthcare, Actavis Totowa, Aiping Pharm Inc, Ascent Pharms Inc, Aurobindo Pharma, Chartwell, Cipla Ltd, Hikma Pharms, Invagen Pharms, Natco, Pliva Hrvatska Doo, Roxane, Sun Pharm, Sun Pharm Inds Ltd, Torrent Pharms, Unichem Labs Ltd, Viwit Pharm, and Wockhardt, and is included in forty-three NDAs. It is available from fifty suppliers. Additional details are available on the TOPIRAMATE profile page.
The generic ingredient in TOPIRAMATE is topiramate. There are twenty-six drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the topiramate profile page.
The generic ingredient in TOPIRAMATE is topiramate. There are twenty-six drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the topiramate profile page.
Summary for 207382
| Tradename: | TOPIRAMATE |
| Applicant: | Zydus |
| Ingredient: | topiramate |
| Patents: | 0 |
Pharmacology for NDA: 207382
| Mechanism of Action | Cytochrome P450 2C19 Inhibitors Cytochrome P450 3A4 Inducers |
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 207382
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TOPIRAMATE | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 207382 | ANDA | Zydus Pharmaceuticals USA Inc. | 68382-358 | 68382-358-01 | 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (68382-358-01) |
| TOPIRAMATE | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 207382 | ANDA | Zydus Pharmaceuticals USA Inc. | 68382-358 | 68382-358-05 | 500 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (68382-358-05) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 25MG | ||||
| Approval Date: | Nov 24, 2017 | TE: | AB1 | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 50MG | ||||
| Approval Date: | Nov 24, 2017 | TE: | AB1 | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 100MG | ||||
| Approval Date: | Nov 24, 2017 | TE: | AB1 | RLD: | No | ||||
Complete Access Available with Subscription
